-+ 0.00%
-+ 0.00%
-+ 0.00%

Spruce Biosciences names Adrian Quartel chief medical officer

PUBT·07/27/2026 12:00:46
Listen to the news
Spruce Biosciences names Adrian Quartel chief medical officer
  • Spruce Biosciences named Adrian Quartel as chief medical officer, effective today, as it targets a BLA filing for tralesinidase alfa in Q4 2026.
  • Quartel joins from Zevra Therapeutics, where he served as chief medical officer leading clinical development, medical affairs, and regulatory strategy across its rare-disease portfolio.
  • He previously held chief medical officer roles at Acer Therapeutics, Adamas Pharmaceuticals, and senior global medical affairs leadership at BioMarin.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607270800BIZWIRE_USPR_____20260727_BW004913) on July 27, 2026, and is solely responsible for the information contained therein.